Overpromising AI capabilities to hospital stakeholders—now there’s a mistake healthcare AI enthusiasts have been known to make.

For the study, researchers had five diabetes specialists judge precision AI tools developed from a large, longitudinal dataset of patients’ individually expressed needs. 

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 

The study's authors reviewed CCTA imaging results taken before and after radiotherapy, evaluating each image for signs of coronary calcification and inflammation. 

Patient outcomes do not appear to be negatively impacted by these risks, researchers noted. The new data were presented at Heart Rhythm 2025 and published in JACC: Clinical Electrophysiology.

Bill Gates wasn’t just wrong to suggest AI will make physicians unnecessary. He was reckless. 

Healthcare may finally have struck a healthy balance between AI hype and AI reality, according to a report from impartial observers who are also, indirectly at least, healthcare AI stakeholders.

AI shines in radiology when tasked with interpreting images of patients whose odds of illness are either very high or very low. In these cases, the technology could help mitigate burnout and supplement staffing.